

ASX RELEASE (17 JULY 2020)

THC Global Completes Capital Raising

Investment Highlights:

- Share Purchase Plan has now closed raising over \$1.5 million taking total capital raise to \$8.1 million at \$0.30 per share
- Funds to be applied towards expanding capability at Southport Facility for additional finished goods, developing IT infrastructure to support doctors and pharmacies in accessing medicinal cannabis, and for working capital

THC Global Group Limited (**THC Global** or the **Company**) (ASX:THC) advises that the Share Purchase Plan (the **SPP**), offered to eligible shareholders, has now closed, raising \$1.535 million from 312 shareholders. The SPP followed the completion an institutional placement in late June 2020, taking the total amount raised by the Company in this capital raising to \$8.136 million.

The funds raised from this capital raising will be primarily applied towards working capital for the Company as production volumes rapidly increase at the Company's Southport Facility. Additionally, part of the funds raised will be applied towards expanding the Company's finished goods capabilities into additional medicine forms, and to develop new IT infrastructure to support doctors and pharmacies supplying medicinal cannabis medicines for both Canndeo and Tetra Health.

Chief Executive Officer, Ken Charteris, commented:

"We're pleased to have now completed this capital raising, securing over \$8.1 million for the Company. Over the past few months, we have achieved a number of significant milestones as a Company including supplying our Canndeo medicine to our first Australian patients, signing production agreements which will see THC Global manufacturing medicines for multiple brands, securing export agreements into New Zealand and soon Canada, and achieving continued patient and revenue growth across the business. We look forward to building on these successes now with a stronger balance sheet to take us forward."

The Company expects allotment and issue of the SPP shares to occur on Monday, 20 July 2020.

For further information, please contact:



Ken Charteris
Chief Executive Officer
e: ceo@thc.global

Sonny Didugu & Jarrod White
Joint Company Secretaries
e: corporate@thc.global
p: +61 2 8088 4760

The Capital Network
Julia Maguire
e: julia@thecapitalnetwork.com.au
p: + 61 2 8999 3699

ASX release authorised by THC Global's Management Committee – the Chairman, Deputy Chairman, and CEO.





THC Global Group Limited (ASX: THC) thc.global

THC Global is a diversified global cannabis company with primary operations in Australia and Canada. THC Global is the first ASX listed entity to fully own and operate end to end commercial medicinal cannabis production facilities under Australia's cannabis regulations. THC Global's Southport Facility in Southport, Australia is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world. THC Global also owns and operates a fast growing turnkey cultivation solutions provider, including a hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sectors in North America and Europe.

For prospective patients or healthcare professionals seeking more information on medicinal cannabis, please visit: canndeocare.com and tetrahealth.com.au.